How to Compare Mega-Filers With Boutique Managers Without Getting Misled by Scale
Raw dollars make giant filers look more decisive than they really are. Percentage weight, concentration, and portfolio role are better comparison tools.
Comparing a giant filer with a boutique manager by raw dollars is one of the fastest ways to misunderstand a 13F. Big institutions can own hundreds of billions of a stock without making it the center of the portfolio. Smaller managers can own far less in dollars while taking much bigger percentage risk.
The Better Comparison Lens
Start with percentage weight, not dollars. Then look at top-five concentration and whether the position is part of a diversified core or a narrow thematic bet.
Platform Examples
Vanguard can own enormous amounts of NVDA, AAPL, and MSFT while still remaining broadly diversified. Oak Grove, on the other hand, turned MU and NVDA into a portfolio-defining semiconductor thesis. Anchor Investment Management is another example where the signal lives in the change rate and the percentage context, not the raw dollar count alone.
How to Use This on 13F Insight
- Ignore raw dollar shock value for the first pass.
- Check the position's percentage of the filing.
- Check how concentrated the top of the portfolio is.
- Only then use dollars as a secondary context layer.
Common Mistakes
- Mistake: Bigger dollar amount means stronger conviction. Reality: Not if the portfolio is vastly larger.
- Mistake: Small funds matter less. Reality: Smaller managers can express much sharper percentage conviction.
- Mistake: The same ticker means the same thesis. Reality: Portfolio role often differs completely by fund size and structure.
FAQ
What is the best metric for comparing filers of different sizes?
Usually percentage weight and concentration, not raw dollars.
When do raw dollars matter?
They matter after you understand weight and role, especially for liquidity or ownership context.
Can the same stock mean two different things in two funds?
Yes. In one fund it may be a benchmark component. In another it may be the thesis itself.
Related Research
Explore all researchFisher’s Q4 2025 filing was still packed with mega-cap tech, but the bigger tell was a giant Treasury and investment-grade corporate bond sleeve built through IEF and VCIT. The next filing will show whether that duration bet was tactical or structural.
Apr 17, 2026
Nuveen’s Q4 2025 filing stayed large-cap and AI-heavy at the top, but the more revealing addition was a sizable fixed-income sleeve through NXUS and NHYB. The next filing will show whether those credit and bond ETFs remain central or fade back out.
Apr 17, 2026
CalPERS used Q4 2025 to keep broad-market exposure high through VOO while still adding to Nvidia, Microsoft, Alphabet and Broadcom. The next filing will show whether the pension giant keeps that simple beta-heavy structure or rotates again.
Apr 17, 2026
AQR’s Q4 2025 filing kept expanding, with AUM rising to $190.63B, 69 new names, and a dramatic Bristol Myers build inside an already broad book. The next filing will show whether the quant giant keeps pressing this expansion or starts normalizing the roster again.
Apr 17, 2026
AllianceBernstein kept Nvidia, Microsoft and Amazon on top in Q4 2025, but new exposure to Intuitive Surgical and aggressive increases in Netflix and ServiceNow made the next filing more interesting than another mega-cap recap. Here is what to watch.
Apr 17, 2026